InvestorsHub Logo
Followers 467
Posts 26912
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 109

Wednesday, 11/07/2012 10:06:17 AM

Wednesday, November 07, 2012 10:06:17 AM

Post# of 291
8:07AM Nektar Therapeutics announces that FDA grants fast track designation to Etirinotecan Pegol (NKTR-102) for the treatment of metastatic breast cancer (NKTR) 8.85 : Co announced that the U.S. Food and Drug Administration has designated etirinotecan pegol (NKTR-102) as a Fast Track development program for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with an anthracycline, a taxane, and capecitabine (ATC). Etirinotecan pegol is a unique, targeted topoisomerase I inhibitor designed using Nektar's proprietary polymer conjugate technology. The drug candidate is currently being evaluated in a Phase 3 study in women with metastatic breast cancer.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NKTR News